Terkko Navigator / Leukemia

Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis

The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK− anaplastic large cell lymphoma by regulating the DNA helicase HELLS

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy

Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq

Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid

Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia

PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia

Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia

A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study

Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications

The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia

Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7

Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia

A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study

ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia

Biomarkers for RBM39 degradation in acute myeloid leukemia

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

In vitro-generated alloantigen-specific Th9 cells mediate antileukemia cytotoxicity in the absence of graft-versus-host disease

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Correction: Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes